Patents by Inventor Hwan Jung Lim

Hwan Jung Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11767297
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: September 26, 2023
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Publication number: 20230039679
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Application
    Filed: September 7, 2022
    Publication date: February 9, 2023
    Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
  • Patent number: 11485711
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 1, 2022
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Patent number: 11464770
    Abstract: Provided is a method for treating or preventing cancer, containing, as an active ingredient, a compound having a specific chemical structure and an activity of inhibiting the formation of a c-Myc/Max/DNA complex, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: October 11, 2022
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyung Chae Jeong, Hwan Jung Lim, Seong Jun Park, Ho Kyung Seo, Kyung Ohk Ahn, Sang Jin Lee, Eun Sook Lee
  • Patent number: 11447469
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 20, 2022
    Assignees: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Publication number: 20220160747
    Abstract: The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of cancer comprising a novel azolopyrimidine heterocyclic compound as an active ingredient, and the pharmaceutical composition for the prophylaxis or treatment of cancer of the present invention can be used as a small molecular immunotherapy anticancer agent which modulates an adenosine pathway by comprising the azolopyrimidine heterocyclic compound.
    Type: Application
    Filed: March 20, 2020
    Publication date: May 26, 2022
    Inventors: Seong Jun PARK, Chang Hoon LEE, Hwan Jung LIM
  • Publication number: 20220017491
    Abstract: The present invention relates to a compound which inhibits the binding of Yes associated protein (YAP) and transcriptional enhancer associate domain (TEAD), a prodrug of same, a hydrate of same, a solvate of same or a pharmaceutically acceptable salt of same, and a composition comprising same as an active ingredient, the compound according to the present invention being able to be applied as an inhibitor which can directly inhibit YAP-TEAD binding in the Hippo pathway which plays a crucial role in the occurrence of cancer.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 20, 2022
    Inventors: Hwan Jung LIM, Seong Jun PARK, Chang Hoon LEE, Kyoung Tai NO, Jiwon CHOI, Hei-Cheul JEUNG, You-keun SHIN, Jong Wan KIM, Xuemei JIN
  • Publication number: 20210315879
    Abstract: Provided is a method for treating or preventing cancer, containing, as an active ingredient, a compound having a specific chemical structure and an activity of inhibiting the formation of a c-Myc/Max/DNA complex, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 27, 2017
    Publication date: October 14, 2021
    Applicants: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyung Chae JEONG, Hwan Jung LIM, Seong Jun PARK, Ho Kyung SEO, Kyung Ohk AHN, Sang Jin LEE, Eun Sook LEE
  • Publication number: 20210047300
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 18, 2021
    Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
  • Publication number: 20210047277
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 18, 2021
    Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
  • Patent number: 10227306
    Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: March 12, 2019
    Assignees: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyung Chae Jeong, Hwan Jung Lim, Seong Jun Park, Ho Kyung Seo, Kyung Ohk Ahn, Sang Jin Lee, Eun Sook Lee
  • Patent number: 10179785
    Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 15, 2019
    Assignee: ST PHARM CO., LTD.
    Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
  • Publication number: 20180186744
    Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 5, 2018
    Applicants: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyung Chae JEONG, Hwan Jung LIM, Seong Jun PARK, Ho Kyung SEO, Kyung Ohk AHN, Sang Jin LEE, Eun Sook LEE
  • Patent number: 9951021
    Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: April 24, 2018
    Assignees: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyung Chae Jeong, Hwan Jung Lim, Seong Jun Park, Ho Kyung Seo, Kyung Ohk Ahn, Sang Jin Lee, Eun Sook Lee
  • Patent number: 9914737
    Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 13, 2018
    Assignee: ST PHARM CO., LTD.
    Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
  • Publication number: 20180029988
    Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: July 28, 2017
    Publication date: February 1, 2018
    Applicants: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyung Chae JEONG, Hwan Jung LIM, Seong Jun PARK, Ho Kyung SEO, Kyung Ohk AHN, Sang Jin LEE, Eun Sook LEE
  • Publication number: 20170166572
    Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Application
    Filed: July 10, 2015
    Publication date: June 15, 2017
    Inventors: Jung Nyoung HEO, Hwan Jung LIM, Kwang Rok KIM, Kyung Jin KIM, Uk Il KIM, Hyung Tae BANG, Ji Hye YOON
  • Publication number: 20170145016
    Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
    Type: Application
    Filed: July 10, 2015
    Publication date: May 25, 2017
    Inventors: Jung Nyoung HEO, Hwan Jung LIM, Kwang Rok KIM, Kyung Jin KIM, Uk Il KIM, Hyung Tae BANG, Ji Hye YOON
  • Patent number: 9018233
    Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: April 28, 2015
    Assignees: Kyung Nong Corporation, Korea Research Institute of Chemical Technology
    Inventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim
  • Publication number: 20150094342
    Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 2, 2015
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, KYUNG NONG CORPORATION
    Inventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim